More importantly, combination of DIM and Herceptin is much more effective than either agent alone in HER-2/neu expressing, breast cancer cells, suggesting that combination-mediated alterations in miR-200, along with inactivation of Akt and NF-κB p65, could be a novel approach for the treatment of patients with breast cancer, particularly for the patients whose tumors express high levels of HER-2/neu. The gene discussed is ERBB2; the disease is breast carcinoma.